🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🥁Excited to invite you to join ASCO #IMGoncCoP! Connect, mentor, and support #IMGs through initiatives on visas, mentorship, community practice, leadership, and more. 🙏We’re looking for members and leads. Please fill our survey with your interest!! 👉forms.gle/L4x4XWR6bd99Us…

Progression-free survival says it all! Nivolumab + Ipilimumab outperforms chemo in MSI-H/dMMR metastatic CRC. -changing the game! #ColorectalCancer #Immunotherapy #Oncology NEJM OncoAlert Myriam Chalabi nejm.org/doi/full/10.10…

Key updates from the ESMO - Eur. Oncology #Guidelines for Cutaneous #Melanoma: 1️⃣IIB-IIC get adj PD1 2️⃣Neoadj pembro or nivo-ipi in clinical stage III (NADINA: EFS 81% vs 54%) ➡️ MPR guides therapy 3️⃣ 1L rela-nivo in PD-L1<1% 4️⃣ TILs after ICI failure annalsofoncology.org/article/S0923-…

Ramadan Kareem to folks who celebrate this month that is much beyond just fasting , but more about reformatting thoughts practices intentions and actions! ☪️

Excellent thought provoking podcast! MayoClinicHealthSystem Jasmine Kamboj, MD, FASCO US spends more on cancer care annually than the entire GDP of 115 countries—an unsustainable trajectory. To bridge gaps in access and outcomes, we must focus on increasing efficiencies and rethinking care

The U.S. FDA has granted priority review to the new drug application seeking the approval of zongertinib for the treatment of adult patients with unresectable or metastatic NSCLC harboring HER2 mutations who have received prior systemic therapy. #lcsm hubs.li/Q03ccbKM0

🚨Save the date🚨 ASCO #IMG Community of Practice Meeting at #ASCO25 ⏰May 30st, 4-6 PM CST 📌Room S103, McCormick Place Join us to discuss barriers & opportunities for IMGs ASCO IMG CoP👉bit.ly/3JmJQwK The ASCO Post #IMGoncCoP #MedEd #MedTwitter

🤩Thrilled for another fantastic #IMGoncCoP meeting ASCO #ASCO25! 🙏With an outstanding lineup of presenters, we'll review the excellent work of our subcommittees, and hear the inspiring #IMG stories and explore ways to better ways to support IMGs. 💫Join us for an engaging

Can’t wait for our 3rd Annual ASCO #IMGoncCOP meeting at #ASCO25! The ASCO Post Nazli Dizman Toni Choueiri, MD Memorial Sloan Kettering Cancer Center MSK Department of Medicine With a stellar lineup including Jasmine Kamboj, MD, FASCO Amin Nassar, MD A pancreatic cancer doctor Karine Tawagi MD Fatemeh Ardeshir, MD

Join us on "Togehter We Thrive" at Emory School of Medicine!! #EAWiMS Winship Cancer Institute of Emory University

🚀Heading to ASCO #ASCO25?🚀 🌟Share your presentation details with us! We’ll highlight your work during #ASCO25! 🔗 tinyurl.com/3etmrk6c Let’s celebrate your achievements together!🎉 #IMGCoP #MedTwitter #MedEd ASCO TECAG OncoAlert The ASCO Post Hem-Onc Fellows Network

🔥🚨OncoAlert Hot off the press. Disappointing (but understandable) news. #Patritumab Deruxtecan (#HER3-DXd) application for #FDA approval in advanced #EGFR+ non-small cell #LungCancer is withdrawn. Withdrawal is based on results from #HERTHENA-Lung02 Phase 3 trial where

It is today!! Please join us for the 3rd Annual ASCO IMG Community of Practice from 4-6 PM CST today (Friday) at S103 at McCormick Place. #IMGoncCoP #ASCO25 Toni Choueiri, MD Nazli Dizman Amin Nassar, MD A pancreatic cancer doctor Jasmine Kamboj, MD, FASCO Karine Tawagi MD Fatemeh Ardeshir, MD

🚨We want to highlight your work during #ASCO25! 💫Share your presentation details with us—we’d love to celebrate your accomplishments! 📌Use MyConnection: tinyurl.com/3etmrk6c 📌Or fill out the spreadsheet: tinyurl.com/3krrhjne ASCO OncoAlert Hem-Onc Fellows Network ASCO TECAG

#ASCO25 IMG CoP was one of a kind! Nazli Dizman Ziad Bakouny, MD, MSc & doctors from all over the 🌏 unpacked their paths and personal experience —J-1 → O-1 → EB1 🛂, years of re-training 🩺, learning new cultures, languages, etc… Mentorship tracks and opportunities, workshops, and the

Winship thoracic oncologists Jennifer Carlisle, MD, and Fatemeh Ardeshir, MD, presented their work during today’s afternoon poster session. Dr. Carlisle discussed the use of tarlatamab for SCLC in the outpatient setting and Dr. Ardeshir covered ctDNA in young-onset NSCLC. #ASCO25

Thank you Winship Cancer Institute of Emory University, Ticiana Batista (Leal) Suresh S. Ramalingam, MD, FASCO Anant Madabhushi for all supports to promote our research and improve care of our lung cancer patients.

Dr Tiseo present ALNeo final results: phase 2 neoadjuvant alectinib #2>>surgery>>adj alectinib 1o: MPR N=33, 28 operated MPR 42% pCR 12% R0 86% #ASCO25

📢 Thrilled to present new paper in Cancer Letters : Multi-site study shows AI radiomics predicts survival in SCLC & identifies high-risk ES-SCLC patients who benefit most from chemoimmunotherapy. Kristin Higgins Prantesh Jain MD, FACP Fatemeh Ardeshir, MD 🔗 doi.org/10.1016/j.canl… #AIOncology

In a study published in NEJM involving more than 1700 patients with cancer-related VTE, reduced-dose apixaban (2.5 mg twice daily) resulted in similar 12-month VTE recurrence rates compared with full-dose (5 mg twice daily) apixaban (2.1 versus 2.8 per cent). However, fewer